Literature DB >> 18541119

Drug delivery to brain tumors.

Jaishri Blakeley1.   

Abstract

A prerequisite for the efficacy of any cancer drug is that it reaches the tumor in therapeutic concentrations. This is difficult to accomplish in most systemic solid tumors because of factors such as variable hypoxia, intratumoral pressure gradients, and abnormal vasculature within the tumors. In brain cancer, the situation is complicated by the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier, which serve as physical and physiologic obstacles for delivery of drugs to the central nervous system. Many approaches to overcome, circumvent, disrupt, or manipulate the BBB to enhance delivery of drugs to brain tumors have been devised and are in active investigation. These approaches include high-dose intravenous chemotherapy, intra-arterial drug delivery, local drug delivery via implanted polymers or catheters, BBB disruption, and biochemical modulation of drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541119      PMCID: PMC3998643          DOI: 10.1007/s11910-008-0036-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  48 in total

1.  Metabolic manipulation of glioblastoma in vivo by retrograde microdialysis of L-2, 4 diaminobutyric acid (DAB).

Authors:  A Tommy Bergenheim; Michael Roslin; Urban Ungerstedt; Anders Waldenström; Roger Henriksson; Gunnar Ronquist
Journal:  J Neurooncol       Date:  2006-06-14       Impact factor: 4.130

2.  Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.

Authors:  Sébastien Bihorel; Gian Camenisch; Michel Lemaire; Jean-Michel Scherrmann
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.200

3.  Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.

Authors:  Svetislava J Vukelja; Stephen P Anthony; James C Arseneau; Barry S Berman; C Casey Cunningham; John J Nemunaitis; Wolfram E Samlowski; Kirk D Fowers
Journal:  Anticancer Drugs       Date:  2007-03       Impact factor: 2.248

4.  Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

Authors:  Jon Weingart; Stuart A Grossman; Kathryn A Carson; Joy D Fisher; Shannon M Delaney; Mark L Rosenblum; Alessandro Olivi; Kevin Judy; Stephen B Tatter; M Eileen Dolan
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

5.  Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.

Authors:  Sandeep Kunwar; Michael D Prados; Susan M Chang; Mitchel S Berger; Frederick F Lang; Joseph M Piepmeier; John H Sampson; Zvi Ram; Philip H Gutin; Robert D Gibbons; Kenneth D Aldape; David J Croteau; Jeffrey W Sherman; Raj K Puri
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

6.  Vascular targeted nanoparticles for imaging and treatment of brain tumors.

Authors:  G Ramachandra Reddy; Mahaveer S Bhojani; Patrick McConville; Jonathan Moody; Bradford A Moffat; Daniel E Hall; Gwangseong Kim; Yong-Eun L Koo; Michael J Woolliscroft; James V Sugai; Timothy D Johnson; Martin A Philbert; Raoul Kopelman; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2006-11-15       Impact factor: 12.531

7.  Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control.

Authors:  Matthew G Ewend; Steven Brem; Mark Gilbert; Robert Goodkin; Paul L Penar; Mahesh Varia; Sharon Cush; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

Review 8.  The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.

Authors:  John F Deeken; Wolfgang Löscher
Journal:  Clin Cancer Res       Date:  2007-03-15       Impact factor: 12.531

Review 9.  Chemotherapy delivery issues in central nervous system malignancy: a reality check.

Authors:  Leslie L Muldoon; Carole Soussain; Kristoph Jahnke; Conrad Johanson; Tali Siegal; Quentin R Smith; Walter A Hall; Kullervo Hynynen; Peter D Senter; David M Peereboom; Edward A Neuwelt
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

Review 10.  Lessons learned in the development of targeted therapy for malignant gliomas.

Authors:  Antonio M P Omuro; Sandrine Faivre; Eric Raymond
Journal:  Mol Cancer Ther       Date:  2007-07       Impact factor: 6.261

View more
  25 in total

Review 1.  Overcoming the blood-brain barrier in chemotherapy treatment of pediatric brain tumors.

Authors:  Linfeng Wu; Xiaoxun Li; Dileep R Janagam; Tao L Lowe
Journal:  Pharm Res       Date:  2013-08-31       Impact factor: 4.200

2.  Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma.

Authors:  Samuel A Jensen; Emily S Day; Caroline H Ko; Lisa A Hurley; Janina P Luciano; Fotini M Kouri; Timothy J Merkel; Andrea J Luthi; Pinal C Patel; Joshua I Cutler; Weston L Daniel; Alexander W Scott; Matthew W Rotz; Thomas J Meade; David A Giljohann; Chad A Mirkin; Alexander H Stegh
Journal:  Sci Transl Med       Date:  2013-10-30       Impact factor: 17.956

3.  Improving Forward Infusion Pressure during Brain Tumor Embolization with the Double Catheter and Coil Technique.

Authors:  Sam Dayawansa; Sneha Konda; Walter S Lesley; Patrick T Noonan; Jason H Huang
Journal:  Neurointervention       Date:  2017-09-05

4.  Methotrexate-loaded chitosan- and glycol chitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors.

Authors:  Adriana Trapani; Nunzio Denora; Giuliano Iacobellis; Johannes Sitterberg; Udo Bakowsky; Thomas Kissel
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

Review 5.  Drug delivery systems, CNS protection, and the blood brain barrier.

Authors:  Ravi Kant Upadhyay
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

Review 6.  Transendothelial Transport and Its Role in Therapeutics.

Authors:  Ravi Kant Upadhyay
Journal:  Int Sch Res Notices       Date:  2014-08-27

Review 7.  Engineering challenges for brain tumor immunotherapy.

Authors:  Johnathan G Lyon; Nassir Mokarram; Tarun Saxena; Sheridan L Carroll; Ravi V Bellamkonda
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

8.  Miniaturized neural system for chronic, local intracerebral drug delivery.

Authors:  Canan Dagdeviren; Khalil B Ramadi; Pauline Joe; Kevin Spencer; Helen N Schwerdt; Hideki Shimazu; Sebastien Delcasso; Ken-Ichi Amemori; Carlos Nunez-Lopez; Ann M Graybiel; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2018-01-24       Impact factor: 17.956

9.  Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging.

Authors:  Liang Han; Derek K Kong; Ming-Qiang Zheng; Sasidhar Murikinati; Chao Ma; Peng Yuan; Liyuan Li; Daofeng Tian; Qiang Cai; Chunlin Ye; Daniel Holden; June-Hee Park; Xiaobin Gao; Jean-Leon Thomas; Jaime Grutzendler; Richard E Carson; Yiyun Huang; Joseph M Piepmeier; Jiangbing Zhou
Journal:  ACS Nano       Date:  2016-03-16       Impact factor: 15.881

Review 10.  New Non-Intravenous Routes for Benzodiazepines in Epilepsy: A Clinician Perspective.

Authors:  Marco Mula
Journal:  CNS Drugs       Date:  2017-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.